Filing Flows › Maravai Lifesciences Holdings (MRVI) › Q1 2025
Maravai Lifesciences Holdings (MRVI) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Maravai Lifesciences Holdings (MRVI) reported revenue of $46.9M for the first quarter 2025 (Q1 2025), -27% from a year earlier and -17% from the quarter before. Operating margin was -104.9%, net loss $52.9M (112.8% of revenue).
Maravai Lifesciences Holdings, Q1 2025: revenue $46.9M (-27% year over year), operating margin -104.9%, net loss $52.9M, operating cash flow −$9.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $46.9M | -17% | -27% |
| Operating profit | −$49.2M | — | — |
| Net earnings | −$52.9M | — | — |
| Operating cash flow | −$9.4M | — | — |
What changed
Revenue was $46.9M in Q1 2025, down 27% year over year and down 17% from the previous quarter. Nucleic Acid Production was the largest line at 61% of revenue. Nucleic Acid Production lost $17.3M year over year (down 38%), 100% of the total change.
Gross margin was 16.5%. Operating costs exceeded revenue by $49.2M, an operating margin of -104.9%. The quarter ended with a net loss of $52.9M, wider than the previous quarter's $46.1M loss. Minority interests bore $22.9M of it: to shareholders the quarter was a loss of $29.9M.
Operating cash flow was −$9.4M. Non-cash charges added back $12.7M of depreciation and amortization and $10.4M of share-based compensation. Working capital and other items added $20.3M. Capital expenditures of $5.2M exceeded it, leaving free cash flow of −$14.6M.
Questions
What was Maravai Lifesciences Holdings' revenue in the first quarter 2025?
Maravai Lifesciences Holdings (MRVI) reported revenue of $46.9M for the first quarter 2025 (Q1 2025), -27% from a year earlier and -17% from the quarter before.
Was Maravai Lifesciences Holdings profitable in the first quarter 2025?
Operating loss was $49.2M (-104.9% of revenue) and net loss $52.9M.